Dinutuximab Combination Therapy for High-Risk Neuroblastoma
Adding dinutuximab to induction chemotherapy, surgery, radiation, stem cell transplantation, and immunotherapy improves outcomes in children with newly diagnosed high‑risk neuroblastoma.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Targeted immunotherapies for anaplastic lymphoma kinase-positive pediatric tumors: current advances and future perspectives
- Coexpression of MYCN and ALK Induces Neuroblastoma-Like Tumors From Human iPS Cell-Derived Cranial Neural Crest Cells.
- Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High‑Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study
- Treatment and Survival of Childhood Neuroblastoma: Evidence from a Population-Based Study in the United States
- Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study